pharma news today glp-1 obesity drugs today Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat and other weight-related conditions Pfizer moves forward with weight-loss

But these data gaps further underscore the need to study this population, as currently, there is "limited or no clinical guidance" on the use of GLP-1s prior to conception, the commentary authors wrote

6 Results from a systematic review and meta-analysis study showed that following discontinuation of weight management medications: Patients are estimated to return to baseline weight within 1.7 years 1,** Results from that same study also highlighted that following discontinuation of weight management medications: Cardiometabolic benefits may be lost, with markers estimated to return to baseline within 1.4 years 1,** Ongoing obesity treatment is needed for maintaining weight loss and improvements in cardiometabolic markers 4 Addressing Discontinuation Starts With Understanding What May Influence Adherence and Persistence 5 Long-term adherence is shaped by multiple, interconnected factorsand ongoing research continues to explore how challenges may interact over time

Although comparisons between tirzepatide and higher doses of dulaglutide (e.g., 4.5 mg) have yet to be done, these data argue against the concept that GIP coagonism can reduce the risk of GI adverse events

Stimulant Use Disorder: There are currently no FDA-approved pharmacotherapies for cocaine or methamphetamine addiction

Who is eligible for GLP-1 weight loss treatment